In the month ahead, Viatris may land history-making FDA biosimilar approvals, while readers will enjoy Generics Bulletin’s usual close coverage of the quarterly financial reports.

In June, the $6bn Organon business, including a healthy biosimilars operation, will begin trading, while Coherus BioSciences aims to file for biosimilar Lucentis with partners Formycon and Bioeq.

In April, four Humira (adalimumab) biosimilars are to be listed on Australia’s Pharmaceutical Benefits Scheme, while first-quarter financial reports will hit the market.

In the month ahead, a key ANDA approval could come for Viatris, while additional competition to Gilead Sciences’ Truvada for PrEP is on the way in the US following Teva and Amneal’s launches.

IGBA chair Sudarshan Jain has indicated that "companies are undergoing the change towards digital health," in the second part of an exclusive interview with Generics Bulletin in which Jain and IGBA secretary general Suzette Kox talk about the pandemic-driven shift towards digitalization and computerization.

In an exclusive interview with Generics Bulletin, IGBA chair Sudarshan Jain said that a resilient and diversified supply chain is critical, but localized production may not be the answer to everything. IGBA secretary general Suzette Kox and Jain discussed key lessons to be learned from COVID-19, the IGBA’s focus on regulatory harmonization, and challenges in driving the adoption of generics, biosimilars and value-added medicines.

In the second part of an exclusive interview with Generics Bulletin, BGMA chief executive Mark Samuels talks about the UK’s new biosimilars licensing pathway, future trade deals and IP, and efforts around repurposing generics, as well as looking ahead to how the UK’s vaccination program could reshape the COVID-19 pandemic.

When Mark Samuels took over leadership of the BGMA earlier this year, he was immediately forced to grapple with the twin pressures of Brexit and the COVID-19 pandemic. However, he tells Generics Bulletin in an exclusive interview, the UK off-patent industry has succeeded in maintaining supply against this difficult backdrop and deserves a more coherent government strategy to support the sector.

Ivabradine exhibited interesting pricing dynamics in the UK in June, with the average cost of the heart failure treatment more than trebling despite the lowest offer in the market remaining stable.

Gentamicin prices saw huge increases in the UK in May, with the average shooting up by almost 600%.

Etoricoxib led the steepest price rises for UK generics in April, with the non-steroidal anti-inflammatory drug seeing average prices almost double.

Etoricoxib, letrozole and trimethoprim experienced triple-digit rises in their average UK trade prices in March, according to the latest figures from WaveData.